
1. antimicrob agents chemother. 2018 mar 27;62(4). pii: e02309-17. doi:
10.1128/aac.02309-17. print 2018 apr.

inactivation plasmepsins 2 3 sensitizes plasmodium falciparum the
antimalarial drug piperaquine.

mukherjee a(1)(2), gagnon d(3), wirth df(2)(4), richard d(1).

author information: 
(1)centre de recherche en infectiologie du chu de québec-université laval, québec
city, québec, canada angana.mukherjee@crchudequebec.ulaval.ca
dave.richard@crchudequebec.ulaval.ca.
(2)harvard t.h. chan school public health, boston, massachussetts, united
states.
(3)centre de recherche en infectiologie du chu de québec-université laval, québec
city, québec, canada.
(4)the broad institute mit harvard, cambridge, massachussetts, united
states.

dihydroartemisinin-piperaquine (dha-ppq), current frontline artemisinin
combination therapy used treat plasmodium falciparum malaria multiple
southeast asian countries, increasingly failing cambodia, where
artemisinin resistance nearly fixed, suggests ppq resistance has
emerged spreading rapidly greater mekong subregion. recent reports 
have shown amplification genes encoding plasmepsins 2 3 a
molecular marker ppq resistance; however, whether enzymes play role in
the mechanism resistance currently unknown. show inactivating 
the genes encoding plasmepsin 2 3 individually p. falciparum reference
strain 3d7 results hypersusceptibility ppq. interestingly, significant
differences susceptibility antimalarials observed, which
suggests specific roles plasmepsins 2 3 ppq susceptibility. the
piperaquine hyper-sensitivity plasmepsin-2-and-3-inactivated lines
provides direct evidence enzymes modulate parasite susceptibility to
ppq context single copy pfmdr1 independent kelch13
mutations conferring artemisinin resistance.

copyright © 2018 american society microbiology.

doi: 10.1128/aac.02309-17 
pmcid: pmc5913920
pmid: 29439977  [indexed medline]

